CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +104 | $19.34 | $2K | 73,493 |
| 2026-08-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +4,896 | $24.59 | $120K | 78,389 |
| 2026-08-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $48.58 | $437K | 69,389 |
| 2026-08-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −104 | 1,252 | ||
| 2026-08-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −4,896 | 66,276 | ||
| 2026-08-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $48.58 | $99K | 225,456 |
| 2026-07-06 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $54.03 | $110K | 227,490 |
| 2026-07-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 82,389 |
| 2026-07-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −8,300 | $51.46 | $427K | 74,089 |
| 2026-07-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −700 | $52.13 | $36K | 73,389 |
| 2026-07-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 1,356 | ||
| 2026-06-12 | Wright Christopher I Director | Sale 10b5-1 | −2,000 | $45.10 | $90K | 25,680 |
| 2026-06-04 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $43.05 | $88K | 229,524 |
| 2026-06-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 86,389 |
| 2026-06-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $41.67 | $375K | 77,389 |
| 2026-06-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 6,356 | ||
| 2026-05-29 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Option exercise | +3,392 | $20.03 | $68K | 11,109 |
| 2026-05-29 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Option exercise | +12,825 | $19.34 | $248K | 23,934 |
| 2026-05-29 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Sale | −16,217 | $42.36 | $687K | 7,717 |
| 2026-05-29 | Parisi Samuel Joseph VP, Finance (Interim PAO) | Option exercise · Employee Stock Option (Right to Buy) | −3,392 | 3,394 |
Page 2 of 41 · 804 trades